Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | PPIA | P62937 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3918747 | 0.81 | TAAR1 (0.55) | KMT2AMEN1LMNAMAPTHPGD | |
| SCHEMBL28269593 | 0.81 | ALDH1A1 (0.47) | KMT2AMEN1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL31344502 | 0.81 | RIPK1 (0.49) | KMT2AMEN1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL5527359 | 0.81 | ALDH1A1 (0.59) | KMT2AMEN1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL10310299 | 0.81 | RIPK1 (0.49) | KMT2AMEN1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL27805137 | 0.78 | TSHR (0.57) | KMT2AMEN1MAPTPKMHTT | |
| SCHEMBL8954327 | 0.77 | NPC1 (0.61) | KMT2AMEN1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL16108114 | 0.77 | KMT2A (0.49) | KMT2ALMNAMAPTRIPK1HPGD | |
| SCHEMBL5523322 | 0.77 | ALDH1A1 (0.54) | KMT2AMEN1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL16108275 | 0.77 | EPHX2 (0.50) | HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115636815-B | Preparation method and application of pomalidomide connected urea compound | 新乡学院 | 2023-10-27 | — | — | CN | disclosed |
| US-9353089-B2 | Compositions and methods for the treatment of malaria | SAINT LOUIS UNIVERSITY (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140296532-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2014-10-02 | — | — | US | disclosed |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
| CN-1169730-A | Aromatic heterocyclic derivatives as enzyme inhibitors | CORVAS INT INC (US) | 1998-01-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | KMT2A 792/4885MEN1 647/4885LMNA 2932/4885 |
| US-20140296532-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA | BACE2, DNPEP, ACE | KMT2A 960/4885MEN1 2432/4885LMNA 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.